KRTX - Karuna Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.75
-0.30 (-1.36%)
As of 1:36PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close22.05
Open22.00
Bid21.56 x 1000
Ask21.92 x 1000
Day's Range21.22 - 22.44
52 Week Range16.95 - 29.00
Volume41,643
Avg. Volume175,037
Market Cap509.228M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1,760.32
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.25
Trade prices are not sourced from all markets
  • Business Wire

    Karuna Therapeutics Reports Second Quarter 2019 Financial Results and Provides General Business Update

    BOSTON-- -- Completed multiple financings in 2019, including initial public offering, raising $184.7 million to fund clinical development of novel CNS pipeline Results from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track to report data in late 2019 Two programs to initiate clinical trials by the end of 2019, including programs for ...

  • Business Wire

    Karuna Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

    Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present at the 2019 Wedbush PacGrow Healthcare Conference at 9:45 a.m.

  • GuruFocus.com

    Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares

    President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.

  • Business Wire

    Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the closing of its initial public offering of 6,414,842 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 836,718 additional shares of common stock, at a public offering ...

  • Benzinga

    Karuna Therapeutics Opens Above IPO Price

    Karuna Therapeutics, Inc. (NASDAQ: KRTX ) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna focuses on developing novel therapies to address disabling ...

  • Business Wire

    Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. In addition, Karuna has granted the underwriters a 30-day option to purchase up to 836,718 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

  • Benzinga

    Karuna Therapeutics IPO: What You Need To Know

    Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week.  The IPO Terms Boston, Massachusetts-based Karuna Therapeutics, ...